AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01833351
Drug: IV Vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.~Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits.
Trial: NCT00759551
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
Trial: NCT01728454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching capsules, orally, once daily for 18 weeks.
Trial: NCT01190839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
Trial: NCT02613910
Drug: Acetaminophen/paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
Trial: NCT03187314
Drug: Radiation
RxNorm normalized name: Miaderm Radiation Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210
Trial: NCT02828098
Drug: Part 1: BO-112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).
Trial: NCT02828098
Drug: Part 2: BO-112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BO-112 at a fixed dose will be administered as an intratumoral injection for up to 5 doses over 12 weeks and continue as long as there is benefit.~Nivolumab will be administered as an intravenous infusion every 2 weeks at a dose of 3 mg/kg for up to a total period of one year.~OR Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year.
Trial: NCT03747497
Drug: contezolid acefosamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV and oral contezolid acefosamil given twice a day for 10 to 14 days
Trial: NCT02058966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules compounded to be of similar appearance to the active drugs
Trial: NCT01926366
Drug: AZD6423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: AZD6423 Single or Multiple doses via infusion.
Trial: NCT01926366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
Trial: NCT03270280
Drug: Nigella Sativa Oil
RxNorm normalized name: Nigella sativa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks
Trial: NCT03270280
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks
Trial: NCT00638248
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo i.v. bolus
Trial: NCT04524663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match camostat mesilate
Trial: NCT04411316
Drug: Anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive anticoagulation alone. Anticoagulation will be heparin only.
Trial: NCT03940352
Drug: HDM201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT01205464
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
Trial: NCT01205464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
Trial: NCT01855919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04024462
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 milligrams per meter squared of body surface area (mg/m\^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
Trial: NCT03937882
Drug: RGN-259
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days
Trial: NCT04024462
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600 mg/m\^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
Trial: NCT03937882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
Trial: NCT01527760
Drug: Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)
RxNorm normalized name: Viscum album stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks
Trial: NCT03999203
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
Trial: NCT02534324
Drug: Antihypertensive meds
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antihypertensive medications will be given to newly-diagnosed or non-compliant cases. The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control. The choices of drugs will be at discretion of treating physicians.
Trial: NCT01963910
Drug: vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application to the other half of the upper lip following capsaicin cream removal
Trial: NCT02314299
Drug: MTP-131
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01664975
Drug: GDPT regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
Trial: NCT01664975
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
Trial: NCT04630067
Drug: AZD3427
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.
Trial: NCT02491463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
Trial: NCT01451203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC)
Trial: NCT01451203
Drug: methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT01249404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.M. injection on day 1 (single treatment cycle)
Trial: NCT00002600
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02043704
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Details covered in arm description.
Trial: NCT01403415
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT01674868
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg daily for 90 days starting day 5-10 after stroke.
Trial: NCT01674868
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will take one pill po daily for 90 days.
Trial: NCT00433979
Drug: antiretroviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These antiretroviral drugs are a part of the participant's current drug regimen.
Trial: NCT00081900
Drug: DENSPM )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive DENSPM at an initial dose of 30mg/m\^2, then escalating to 120mg/m\^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
Trial: NCT03866824
Drug: injection of corticosteroids
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra-articular injection
Trial: NCT06597903
Drug: NRL994
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the afternoon/evening before colonoscopy: 1 litre solution plus 0.5 litre clear fluid.~Day of colonoscopy: 1 litre solution plus at least up to 1 litre clear liquid.
Trial: NCT01370499
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01933542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo tablets identical to the chlorzoxazone tablets.
Trial: NCT01211860
Drug: Diazoxide Choline Controlled-Release Tablet
RxNorm normalized name: diazoxide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCCR 290 mg once a day for 10 days
Trial: NCT02452320
Drug: intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
Trial: NCT02452320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
Trial: NCT03382639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luvadaxistat placebo-matching tablets.
Trial: NCT02360358
Drug: Tiscover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two step procedure, week 0 and week1. Dosage depends on wound size.
Trial: NCT00987558
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03198559
Drug: Disulfiram, (National Drug Code) NDC 0378-4141-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will provide open label disulfiram. Participants will take 2 grams (4x500mg tablets) of disulfiram per day for a total of 28 days
Trial: NCT02812602
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
Trial: NCT03230240
Drug: HIPEC
RxNorm normalized name: Hyperthermic Intraperitoneal Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heated intraIP chemotherapy
Trial: NCT02492321
Drug: EBI-005
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02492321
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03672006
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication administered to dwell in central venous catheter
Trial: NCT02479022
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
Trial: NCT02419443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group
Trial: NCT01430559
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7.5mg x2 once a day for 12 weeks
Trial: NCT04686591
Drug: AZD9977 capsule 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)
Trial: NCT00504595
Drug: ACZ885 (investigational)
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Trial: NCT00504595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Trial: NCT03016520
Drug: DWJ1392
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04589260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be administered by oral inhalation
Trial: NCT03252223
Drug: Recombinant Follicle Stimulating Hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.
Trial: NCT02557269
Drug: Prednisolone 5 mg
RxNorm normalized name: prednisolone 5 MG
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Per os - if needed (only in case of broncial obstruction)
Trial: NCT02467504
Drug: hrIL-2 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
Trial: NCT02467504
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid (oral administration)
Trial: NCT01432470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
Trial: NCT03190304
Drug: Neprilysin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
Trial: NCT02208466
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
Trial: NCT02208466
Drug: Placebo Fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
Trial: NCT03778281
Drug: Methoxyclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of metoclopramide 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
Trial: NCT03244280
Drug: MOB015B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation
Trial: NCT01843829
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02297867
Drug: ADSCs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: autologous ADSCs
Trial: NCT04301557
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000mg/m\^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen
Trial: NCT02121535
Drug: T80/A5 mg FDC tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02121535
Drug: T80/A5 mg FDC tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet
Trial: NCT02121535
Drug: H12.5 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02121535
Drug: T80/A5/H12.5 ng FDC tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet
Trial: NCT02121535
Drug: H12.5 mf tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A HCTZ 12.5 mg tablet
Trial: NCT02121535
Drug: T80/A5/H12.5 mg FDC tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01273012
Drug: Probiotic - Infloran
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
Trial: NCT02661789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of saline
Trial: NCT00411229
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
Trial: NCT02911285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills bid
Trial: NCT01397409
Drug: AGN-150998
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-150998 Intravitreal injection.
Trial: NCT02218424
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01013805
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.~Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1
Trial: NCT01013805
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
Trial: NCT00394173
Drug: DNK333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNK333 25mg b.i.d. given orally for 4 weeks
Trial: NCT00394173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01265511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets given bid for 28 days
Trial: NCT03763084
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients in the acetaminophen group, oral acetaminophen supplemented dexmedetomidine sedation will be provided after surgery.
Trial: NCT03763084
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patients in the control group, sufentanil supplemented dexmedetomidine sedation will be provided after surgery.
Trial: NCT02760420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
Trial: NCT03574584
Drug: NNC0165-1562
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
Trial: NCT03574584
Drug: Placebo (NNC0165-1562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.